NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Kymera Therapeutics, Inc. (KYMR) Stock Analysis

Kymera Therapeutics, Inc. (KYMR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KYMR

$112.63

−$0.83 (−0.73%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KYMR with… →

KYMR Key Statistics

As of Oct 21, 2026
Trading
Open
$113.38
Previous Close
$113.46
Day's Range
112.52–115.75
52-Week Range
55.26–130.05
Volume
1.04M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.98
Valuation
Market Cap
$9.26B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
88.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.25
Financials (FY)
Revenue (FY)
$39.21M−16.70%
Net Income (FY)
−$311.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
−285.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
82.26M
1-Year Return
+93.12%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
728.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KYMR closed at $112.63, +93.12% over 1 year.

Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $9.26B.

In fiscal 2025, KYMR reported revenue of $39.21M.

KYMR Stock Return by Calendar Year

Kymera Therapeutics, Inc. (KYMR) return since Aug 2020: what $10,000 became

1 year
$10,000 $19,312
+93.12%
5 years
$10,000 $20,564
+105.64%
Since Aug 2020
$10,000 $33,863
+238.63%

If you had invested $10,000 in Kymera Therapeutics, Inc. (KYMR) at the close on August 21, 2020, the earliest close on record here, it would have been worth $33,863 at the close on October 21, 2026: +238.63% in total, +21.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+44.75%
2025+93.41%
2024+58.01%
2023+2.00%
2022−60.69%
2021+2.40%
2020 (partial year)+86.41%

As of October 21, 2026.

KYMR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$39.21M−$311.35M−794.0%
2024$47.07M−$223.86M−475.6%
2023$78.59M−$146.96M−187.0%
2022$46.83M−$154.81M−330.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$39.21M—−$345.54M−$311.35M−794.0%
2024$47.07M—−$256.71M−$223.86M−475.6%
2023$78.59M—−$165.53M−$146.96M−187.0%
2022$46.83M—−$161.26M−$154.81M−330.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KYMR Valuation vs Biotechnology Median

Median of 608 stocks
MetricKYMRBiotechnology medianvs median
P/S ratio88.2313.306.6x the median
Profit margin−285.33%−38.31%247.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kymera Therapeutics, Inc. (KYMR) at $9.26B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 273 employees.

The most recent close on file for KYMR is $112.63, dated October 21, 2026. That is −$0.83 (−0.73%) against the previous close. The 52-week range on file runs from $55.26 to $130.05. The latest close sits 103.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $39.21M. Against the prior fiscal year total of $47.07M, that is a change of −16.70%. The same year closed with a net loss of $311.35M. The reported profit margin is −285.33%. That is 247 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −3.25.

Across the 4 fiscal years on file, revenue moves from $46.83M in 2022 to $39.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 88.23 times revenue. On price-to-sales that is 6.6 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +93.12%. Across 5 years the annualized return works out at +15.51%. Beta against the wider market is reported at 1.98. Annualized volatility over the trailing 6 years is 73.62%.

Growth & Income

No dividend is on file for KYMR.

The strongest complete calendar year on file is 2025 at +93.41%; the weakest is 2022 at −60.69%. Of the 5 complete calendar years on file, 4 finished higher. So far in 2026 the total return is +44.75%.

Peer Comparison

Kymera Therapeutics, Inc. (KYMR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kymera Therapeutics, Inc. KYMR $9.26B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Kymera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit website →